Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases. With more than 1,700 employees, Biocodex generated net revenues of above €500 million in 2023, including 1/3 in France and 2/3 internationally. The group is present in more than 100 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide. To report quality complaint(s) or adverse event(s) related to Biocodex products please visit https://www.biocoreport.com/en/